Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma
Immunotherapy-Chemo Mix Shows Promise Against Stubborn Skin Cancer
This case report and literature review describes a 78-year-old female with porocarcinoma treated with penpulimab plus nab-paclitaxel, then a…
• A rare skin cancer slowed with immunotherapy plus chemo • Helps patients with porocarcinoma lacking treatment options • Still experimental
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC
Early trial shows firmonertinib plus anlotinib helps some advanced lung cancer patients
This single-arm, phase I/II trial evaluated firmonertinib combined with anlotinib in patients with advanced non-small cell lung cancer (NSCL…
Combining firmonertinib and anlotinib helped 64% of advanced lung cancer patients shrink tumors and keep disease controlled for over a year …